

October 7, 2024

The General Manager,
Department of Corporate
Services
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai 400001

Manager – Listing Compliance
**National Stock Exchange of
India Ltd.**
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E) Mumbai 400051

Dear Sir/Madam,

Company scrip code in BSE: 512529
Company's symbol in NSE: SEQUENT
ISIN: INE807F01027

Sub: Compliance report to be submitted along with the draft scheme in accordance with Master Circular number SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by the Securities and Exchange Board of India ("SEBI Scheme Circular").

It is hereby certified that the draft composite scheme of amalgamation amongst SeQuent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited and their respective shareholders and creditors under Sections 230 to 232 of the Companies Act, 2013 ("**Scheme**") does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchange(s) and the same is in compliance with the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR Regulations**") and the SEBI Scheme Circular, including the following:

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

	Reference	Particulars	Remarks
	Regulations 17 to 27 of LODR Regulations	Corporate governance requirements	In compliance
	Regulation 11 of LODR Regulations	Compliance with securities laws	In compliance
Requirements of the SEBI Scheme Circular			
	Para (I)(A)(2)	Submission of documents to Stock Exchanges	In compliance
	Para (I)(A)(3)	Conditions for schemes of arrangement involving unlisted entities	We undertake to comply with the requirement specified in Para (A)(3) of Part I in relation to the draft Scheme involving unlisted entities as applicable.
	Para (I)(A)(4)(a)	Submission of Valuation Report	In compliance
	Para (I)(A)(5)	Auditors certificate regarding compliance with Accounting Standards	In compliance

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

	Para (I)(A)(10)	Provision of approval of public shareholders through e-voting	Approval of the public shareholders of Sequent Scientific Limited as required under para (I)(A)(10) of Part I of the SEBI Scheme Circular is applicable. This requirement relating to the approval of the public shareholders through e- voting will be complied with. Hence this undertaking has not been provided.
--	--------------------	---	---

Yours sincerely,
For and on behalf of **SeQuent Scientific Limited**

Phillip Trott
Company Secretary
Membership No. 7403

Rajaram Narayanan
Managing Director
DIN: 02977405

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Certified that the transactions / accounting treatment provided in the draft composite scheme of amalgamation amongst SeQuent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited and their respective shareholders and creditors under Sections 230 to 232 of the Companies Act, 2013 and their respective shareholders and creditors under Sections 230 to 232 of the Companies Act, 2013 and other applicable laws are in compliance with all the accounting standards applicable to a listed entity.

Yours sincerely,
For and on behalf of **SeQuent Scientific Limited**

Saurav Bhala
Chief Financial Officer

Rajaram Narayanan
Managing Director
DIN: 02977405

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in